Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- assertion label "Defining a publication info template" assertion.
- tgstatementref label "short ID of grouped statement" assertion.
- tstatementx label "short ID of simple statement" assertion.
- placeholder label "placeholder mentioned above" assertion.
- placeholderWithPossibleValuesFromApi label "guided choice placeholder" assertion.
- possiblevaluesfromapi label "URL prefix for API lookup" assertion.
- placeholderWithPossibleValues label "restr/guided choice placeholder" assertion.
- labeled label "URI/placeholder mentioned above" assertion.
- possiblevaluesfrom label "nanopublication with possible values" assertion.
- prefix label "URL prefix" assertion.
- placeholderWithRegex label "short ID of placeholder" assertion.
- tpred label "URI/placeholder of the predicate" assertion.
- torder label "integer value for statement order" assertion.
- group label "short ID of grouped statement" assertion.
- placeholderWithPossibleValuesFrom label "restr/guided choice placeholder" assertion.
- tsubj label "URI/placeholder of the subject" assertion.
- tobj label "URI/literal/placeholder of the object" assertion.
- statementWithStatementOrder label "short ID of statement" assertion.
- possiblevalue label "possible value" assertion.
- prefixlabel label "label for URL prefix" assertion.
- tstatement label "short ID of simple statement" assertion.
- placeholderWithPrefix label "short ID of placeholder" assertion.
- tlabel label "name of this template" assertion.
- tstatementa label "short ID of statement" assertion.
- regex label "regular expression" assertion.
- tstatementi label "short ID of statement" assertion.
- label label "label of thing" assertion.
- assertion label "Defining a provenance template" assertion.
- step label "awesome smoothening of an image" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- text label "text" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- step label "Add an awesome Watermark to your image (licence:cc0,author:rsiebes, date:06-05-2021 )" assertion.
- cohort label "Adults" assertion.
- association label "Pitolisant and sodium oxybate show promising results in two retrospective studies. The efficacy of γ-aminobutyric acid-A receptor antagonists on objective EDS needs to be clarified. All these medications are used off-label for the management of EDS in IH." assertion.
- HP_0001262 label "Excessive day time somnolence" assertion.
- cohort label "Children" assertion.
- association label "Dextroamphetamine-containing extended-release formulations (n = 180) and atomoxetine (n = 103) were also frequently prescribed off-label medications for children ages 3 to 5 years (8.1% and 4.6%, respectively)." assertion.
- cohort label "Children" assertion.
- association label "The 2 other medications for which off-label prescriptions were written for children ages 3 to 5-years included dexmethylphenidate, both immediate (20/2233) and extended release (20/2233), and lisdexamfetamine (42/2233)." assertion.
- association label "The most commonly prescribed off-label prescriptions for children ages 3 to 5 years were methylphenidate and alpha agonist formulations" assertion.
- cohort label "Children" assertion.
- association label "lenvima is a kinase inhibitor that is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodine refractory differentiated thyroid cancer dtc 1 1 in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior anti angiogenic therapy 1 2 for the first line treatment of patients with unresectable hepatocellular carcinoma hcc 1 3 lenvima is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodine refractory differentiated thyroid cancer dtc lenvima is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior anti angiogenic therapy lenvima is indicated for the first line treatment of patients with unresectable hepatocellular carcinoma hcc" assertion.
- comment label "This comment" assertion.
- ReferredObject label "identifier of the object that is reviewed (e.g. a text or nanopublication)" assertion.
- reviewComment label "The content of this comment as free text" assertion.
- ReferredMentioning label "identifier of a thing mentioned in the object that is reviewed" assertion.
- impact label "integer value from 1 (low impact) to 5 (high impact)" assertion.
- assertion label "Making a review comment according to the LinkFlows model" assertion.
- refersToMentioningOf label "refers to the mentioning of" assertion.
- refersToMentioningOf label "refers to the mentioning of" assertion.
- refersToMentioningOf label "refers to the mentioning of" assertion.
- refersToMentioningOf label "refers to the mentioning of" assertion.
- refersToMentioningOf label "refers to the mentioning of" assertion.
- refersToMentioningOf label "refers to the mentioning of" assertion.
- image label "image" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "AWESOME upside down flipper" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- image label "image" assertion.
- list-rest label "a rest-list" assertion.
- class2 label "URI of existing class 2" assertion.
- name label "the name of the class" assertion.
- class1 label "URI of existing class 1" assertion.
- newclass label "short ID of new class" assertion.
- list label "a list" assertion.
- intersectionOrUnion label "select intersection or union" assertion.
- description label "description of the class" assertion.
- assertion label "Defining a new class by intersection or union" assertion.
- step label "add awesome filters" assertion.
- image_path label "image_path" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- association label "activase is a tissue plasminogen activator tpa indicated for the treatment of acute ischemic stroke ais 1 1 acute myocardial infarction ami to reduce mortality and incidence of heart failure 1 2 limitation of use in ami 1 2 acute massive pulmonary embolism pe for lysis 1 3 activase is indicated for the treatment of acute ischemic stroke exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment see contraindications 4 1 activase is indicated for use in acute myocardial infarction ami for the reduction of mortality and reduction of the incidence of heart failure limitation of use activase is indicated for the lysis of acute massive pulmonary embolism defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments acute pulmonary emboli accompanied by unstable hemodynamics e g failure to maintain blood pressure without supportive measures" assertion.
- association label "pulmozyme r in cf patients with an fvc 4 of predicted daily administration of pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics pulmozyme is a recombinant dnase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis cf patients to improve pulmonary function 1" assertion.
- association label "oncaspar is an asparagine specific enzyme indicated as a component of a multi agent chemotherapeutic regimen for treatment of pediatric and adult patients with first line acute lymphoblastic leukemia 1 1 acute lymphoblastic leukemia and hypersensitivity to asparaginase 1 2 oncaspar r is indicated as a component of a multi agent chemotherapeutic regimen for the first line treatment of pediatric and adult patients with all oncaspar is indicated as a component of a multi agent chemotherapeutic regimen for the treatment of pediatric and adult patients with all and hypersensitivity to native forms of l asparaginase" assertion.
- association label "ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy ninlaro is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy 1" assertion.
- association label "portrazza tm is an epidermal growth factor receptor egfr antagonist indicated in combination with gemcitabine and cisplatin for first line treatment of patients with metastatic squamous non small cell lung cancer 1 1 limitation of use portrazza is not indicated for treatment of non squamous non small cell lung cancer 1 2 5 6 14 2 portrazza tm is indicated in combination with gemcitabine and cisplatin for first line treatment of patients with metastatic squamous non small cell lung cancer portrazza is not indicated for treatment of non squamous non small cell lung cancer see warnings and precautions 5 6 14 2" assertion.
- association label "zurampic is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone s ee clinical studies 14 zurampic is a urat1 inhibitor indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone 1 limitations of use zurampic is not recommended for the treatment of asymptomatic hyperuricemia 1 1 zurampic should not be used as monotherapy 1 1 5 1 zurampic is not recommended for the treatment of asymptomatic hyperuricemia zurampic should not be used as monotherapy see warnings and precautions 5 1" assertion.
- association label "kineret is an interleukin 1 receptor antagonist indicated for rheumatoid arthritis ra reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards 1 1 cryopyrin associated periodic syndromes caps treatment of neonatal onset multisystem inflammatory disease nomid 1 2 kineret is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis ra in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards kineret can be used alone or in combination with dmards other than tumor necrosis factor tnf blocking agents see warnings and precautions 5 2 kineret is indicated for the treatment of neonatal onset multisystem inflammatory disease nomid" assertion.
- association label "somavert is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy or for whom these therapies are not appropriate the goal of treatment is to normalize serum insulin like growth factor i igf i levels somavert is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy or for whom these therapies are not appropriate the goal of treatment is to normalize serum insulin like growth factor i igf i levels 1" assertion.
- association label "genotropin is a recombinant human growth hormone indicated for pediatric 1 1 adult 1 2 genotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone genotropin is indicated for the treatment of pediatric patients who have growth failure due to prader willi syndrome pws the diagnosis of pws should be confirmed by appropriate genetic testing see contraindications 4 genotropin is indicated for the treatment of growth failure in children born small for gestational age sga who fail to manifest catch up growth by age 2 years genotropin is indicated for the treatment of growth failure associated with turner syndrome genotropin is indicated for the treatment of idiopathic short stature iss also called non growth hormone deficient short stature defined by height standard deviation score sds 2 25 and associated with growth rates unlikely to permit attainment of adult height in the normal range in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means genotropin is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria adult onset ao childhood onset co patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults according to current standards confirmation of the diagnosis of adult growth hormone deficiency in both" assertion.
- association label "aldurazyme r aldurazyme has been shown to improve pulmonary function and walking capacity aldurazyme has not been evaluated for effects on the central nervous system manifestations of the disorder aldurazyme is a hydrolytic lysosomal glycosaminoglycan gag specific enzyme indicated for patients with hurler and hurler scheie forms of mucopolysaccharidosis i mps i and for patients with the scheie form who have moderate to severe symptoms the risks and benefits of treating mildly affected patients with the scheie form have not been established aldurazyme has been shown to improve pulmonary function and walking capacity aldurazyme has not been evaluated for effects on the central nervous system manifestations of the disorder 1" assertion.
- association label "enbrel is a tumor necrosis factor tnf blocker indicated for the treatment of rheumatoid arthritis ra 1 1 polyarticular juvenile idiopathic arthritis jia in patients aged 2 years or older 1 2 psoriatic arthritis psa 1 3 ankylosing spondylitis as 1 4 plaque psoriasis pso in patients 4 years or older 1 5 enbrel is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis ra enbrel can be initiated in combination with methotrexate mtx or used alone enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis jia in patients ages 2 and older enbrel is indicated for reducing signs and symptoms inhibiting the progression of structural damage of active arthritis and improving physical function in patients with psoriatic arthritis psa enbrel can be used with or without methotrexate enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis as enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy" assertion.
- association label "brovana inhalation solution is a long acting beta 2 2 long term twice daily morning and evening administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema 1 1 important limitations of use brovana inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease 1 2 5 2 brovana inhalation solution is not indicated to treat asthma 1 2 brovana arformoterol tartrate inhalation solution is indicated for the long term twice daily morning and evening maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema brovana inhalation solution is for use by nebulization only brovana inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease see warnings and precautions 5 2 brovana inhalation solution is not indicated to treat asthma the safety and effectiveness of brovana inhalation solution in asthma have not been established" assertion.
- association label "uloric is a xanthine oxidase xo inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol who are intolerant to allopurinol or for whom treatment with allopurinol is not advisable for the safe and effective use of allopurinol see allopurinol prescribing information uloric is a xanthine oxidase xo inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol who are intolerant to allopurinol or for whom treatment with allopurinol is not advisable 1 for the safe and effective use of allopurinol see allopurinol prescribing information limitations of use uloric is not recommended for the treatment of asymptomatic hyperuricemia 1 limitations of use uloric is not recommended for the treatment of asymptomatic hyperuricemia" assertion.
- association label "lantus is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus important limitations of use lantus is not recommended for the treatment of diabetic ketoacidosis intravenous short acting insulin is the preferred treatment for this condition lantus is a long acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus 1 important limitations of use not recommended for treating diabetic ketoacidosis use intravenous short acting insulin instead" assertion.
- association label "imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 1 1 juvenile idiopathic arthritis jia 1 2 psoriatic arthritis psa 1 3 ankylosing spondylitis as 1 4 adult crohn s disease cd 1 5 ulcerative colitis uc 1 6 plaque psoriasis ps 1 7 imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other non biologic disease modifying anti rheumatic drugs dmards imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and 3 kg 66 lbs imraldi can be used alone or in combination with methotrexate imraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with non biologic dmards imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis imraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab imraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6 mercaptopurine 6 mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 14 7 imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warning 5" assertion.
- association label "imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 1 1 juvenile idiopathic arthritis jia 1 2 psoriatic arthritis psa 1 3 ankylosing spondylitis as 1 4 adult crohn s disease cd 1 5 ulcerative colitis uc 1 6 plaque psoriasis ps 1 7 imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other non biologic disease modifying anti rheumatic drugs dmards imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and 3 kg 66 lbs imraldi can be used alone or in combination with methotrexate imraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with non biologic dmards imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis imraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab imraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6 mercaptopurine 6 mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 14 7 imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warning 5" assertion.
- association label "zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed chronic lymphocytic leukemia cll in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co morbidities 1 1 relapsed follicular b cell non hodgkin lymphoma fl in patients who have received at least two prior systemic therapies 1 2 relapsed small lymphocytic lymphoma sll in patients who have received at least two prior systemic therapies 1 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of any patient 1 1 1 2 1 3 zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl 1 2 accelerated approval was granted for fl and sll based on overall response rate improvement in patient survival or disease related symptoms has not been established continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials zydelig is indicated in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia cll for whom rituximab alone would be considered appropriate therapy due to other co morbidities limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with cll zydelig is indicated for the treatment of patients with relapsed follicular b cell non hodgkin lymphoma fl who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 2 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with fl zydelig is not indicated and is not recommended in combination with bendamustine and or rituximab for the treatment of fl zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma sll who have received at least two prior systemic therapies accelerated approval was granted for this indication based on overall response rate see clinical studies 14 3 limitation of use zydelig is not indicated and is not recommended for first line treatment of patients with sll" assertion.
- association label "jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease limitations of use jardiance is a sodium glucose co transporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease 1 limitations of use 1" assertion.
- association label "teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis teriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis 1" assertion.
- association label "invokana r as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of major adverse cardiovascular events cardiovascular death nonfatal myocardial infarction and nonfatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease cvd invokana is a sodium glucose co transporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease 1 limitations of use not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis 1 limitations of use invokana is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis" assertion.